Drug intelligence / Profile preview

IPL-577

Development stage: Preclinical
Lead developer: Immunity Pharma
Modality: Peptides

Overview

IPL-577 is a synthetic peptide drug candidate developed by Immunity Pharma. It is being investigated primarily for the treatment of Parkinson's disease and potentially other nervous system diseases, as well as endocrinology and metabolic diseases. The drug is currently in preclinical development, and detailed information about its mechanism of action or specific molecular targets has not been disclosed publicly[1].

Beyond the preview

Go deeper on IPL-577.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPL-577.

Explore the full profile